JNJ-55308942 (30 mg/kg; p.o.) attenuates LPS-induced microglial activation in mice.
In a model of Bacillus Calmette-Guerin (BCG)-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07 mg/kg. The P2X7 antagonist (3 mg/kg, oral) blocked Bz-ATP-induced brain IL-1β release in conscious rats, demonstrating functional effects of target engagement in the brain.
JNJ-55308942 (5 mg/kg; p.o.) shows the F, Vss, CL, Cmax and AUC24h values are 81%, 1.7 L/kg, 3.7 mL min/kg, 1747 ng/mL, and 17549 (ng/mL) h, respectively.
Animal Model: |
Sixteen male C57/BL6J mice |
Dosage: |
30 mg/kg |
Administration: |
P.o. (after an i.p. injection of LPS (0.8 mg/kg, i.p.)) |
Result: |
Significantly attenuated the effect of LPS on FSC, CD45 surface expression and CD11b surface expression.
|
Animal Model: |
Rat |
Dosage: |
P.o. (Pharmacokinetic Analysis) |
Administration: |
5 mg/kg |
Result: |
The F, Vss, CL, Cmax and AUC24h were 81%, 1.7 L/kg, 3.7 mL min/kg, 1747 ng/mL, and 17549 (ng/mL) h, respectively.
|